AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance.
Saved in:
| Title: | AS01 |
|---|---|
| Authors: | Tregunno C; GSK, London, UK., Deraedt Q; GSK, Av. Fleming 20, 1300, Wavre, Belgium. quentin.x.deraedt@gsk.com., Cuadripani S; GSK, Stevenage, UK., Verheust C; GSK, Av. Fleming 20, 1300, Wavre, Belgium., Bryan P; GSK, London, UK. |
| Source: | Drug safety [Drug Saf] 2026 Aug 01. Date of Electronic Publication: 2026 Aug 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1942 (Electronic) Linking ISSN: 01145916 NLM ISO Abbreviation: Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42541670 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: AS01<subscript>E</subscript>-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tregunno+C%22">Tregunno C</searchLink>; GSK, London, UK.<br /><searchLink fieldCode="AU" term="%22Deraedt+Q%22">Deraedt Q</searchLink>; GSK, Av. Fleming 20, 1300, Wavre, Belgium. quentin.x.deraedt@gsk.com.<br /><searchLink fieldCode="AU" term="%22Cuadripani+S%22">Cuadripani S</searchLink>; GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Verheust+C%22">Verheust C</searchLink>; GSK, Av. Fleming 20, 1300, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Bryan+P%22">Bryan P</searchLink>; GSK, London, UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229002928%22">Drug safety</searchLink> [Drug Saf] 2026 Aug 01. <i>Date of Electronic Publication: </i>2026 Aug 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9002928 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1942 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201145916%22">01145916 </searchLink><i>NLM ISO Abbreviation: </i>Drug Saf <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42541670 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s40264-026-01698-y Languages: – Code: eng Text: English Titles: – TitleFull: AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tregunno C – PersonEntity: Name: NameFull: Deraedt Q – PersonEntity: Name: NameFull: Cuadripani S – PersonEntity: Name: NameFull: Verheust C – PersonEntity: Name: NameFull: Bryan P IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2026 Aug 01 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1179-1942 Titles: – TitleFull: Drug safety Type: main |
| ResultId | 1 |
